ARVO 2025: Analysis of birdshot retinochoroidopathy.
At ARVO 2025, in Salt Lake City, Utah, C Michael Samson, MD, MBA, gave insight into his data on immune cell profiling in birdshot retinochoroidopathy using single-cell RNA sequencing.
New bill expands scope of practice for West Virginia optometrists
The bill, which passed on May 1, allows for West Virginian ODs to provide certain in-office procedures such as laser treatments
Q&A: Joaquin De Rojas, MD, on ASCRS 2025 Best Paper of Session for advancing AK with machine learning
A machine learning model incorporating treated astigmatism and nuanced inputs is advancing the precision and personalization of arcuate keratotomy planning
Q&A: Rishi Singh, MD, discusses real-world outcomes of patients with DME treated with faricimab
Rishi Singh, MD, discusses faricimab's real-world effectiveness in treating diabetic macular edema, highlighting improved vision and reduced treatment frequency.
AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
AAVantgarde Bio reveals promising safety and efficacy data for AAV-based therapies targeting Usher syndrome and Stargardt disease at ARVO 2025.
Q&A: Anat Loewenstein, MD, and results of a consensus group on managing diabetic retinopathy
LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System
LumiThera's Valeda system offers groundbreaking non-invasive treatment for dry AMD, showing extended vision improvement and safety over 4.5 years.
Q&A: Christine Kay, MD, gives an investigator's perspective on the PRISM clinical trial
Nicox releases results from Whistler phase 3b trial in IOP-lowering eye drops
NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).
Structure-function link between ellipsoid zone integrity features and visual acuity in eyes with GA
A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.
Positive preclinical data on melanocortin agonists for retinopathy
Palatin Technologies reveals groundbreaking preclinical results on melanocortin agonists, showcasing their potential to combat diabetic retinopathy and preserve vision.
ARVO 2025: Update on the LIGHTSITE III study in AMD
At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.
ARVO 2025: Post-hoc analysis on GATHER 2 clinical trial data
Giullia Coradetti, MD, offered insight into her research on a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration.
EyeCool Therapeutics announces results from pilot study of novel chronic ocular surface pain treatment
Baseline status of the central subfield ellipsoid zone predicts future visual loss
A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in geographic atrophy patients, highlighting early intervention opportunities.
ARVO 2025: Stromal keratitis in the ZED study
Christina Prescott, MD, talks about the rate of recurrence of stromal keratitis in the Zoster Eye Disease Study, both in the placebo and in the treatment group.
Living with GA: How patients in the US and Western Europe cope
A recent study reveals how geographic atrophy affects patients' vision and quality of life, highlighting their coping strategies and need for better resources.
ARVO 2025: First in-human clinical trials results from magnetic cell therapy
Ellen Koo, MD, presented data from first in-human clinical trials, looking at the results from magnetic cell therapy and reports on the efficacy and safety in the patients.
OCTA role in retinal microvascular changes in SLE patients
ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
Perfluorohexyloctane demonstrated rapid symptom relief in patients with dry eye, with effects reported as early as 5 minutes after dosing.
Hypoglycemia may promote a breakdown of the blood-retinal barrier
New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.
Potentially hazardous eye care products recalled nationwide
Nationwide recall of over 70,000 eye care products due to safety risks prompts consumers to return items for full credit.
CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
CCOI transforms ophthalmic innovation by uniting stakeholders, streamlining processes, and prioritizing patient perspectives for faster, impactful solutions.
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience
Discover how real-world evidence shapes cataract surgery practices, highlighting user satisfaction with enhanced monofocal IOLs at the 2025 ASCRS Annual Meeting.
RWC 2025: BCVA and CST Improvement over 12 weeks with OCS-01 eye drops for DME
Almeida highlighted the increasing prevalence of diabetic macular edema and the importance of developing safe, well-tolerated treatments.
At CIME 2025, Neda Shamie, MD, answers questions about Demodex blepharitis
Q&A: Carl D. Regillo, MD, shares updates on the VERONA trial for DME
Carl D. Regillo, MD, shares insights on the VERONA trial of EYP-1901 at the Retina World Congress 2025 meeting held in Fort Lauderdale, Florida.
Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops
Discover how dropless cataract surgery enhances patient comfort and outcomes, reducing the need for eye drops and improving recovery efficiency.
Q&A: Dilsher S. Dhoot, MD, on the HELIOS trial for diabetic retinopathy
At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs)
